GenoMed, Inc. ("the Company" or "GenoMed") (Pink Sheets: GMED - News), a medical genomics and Next Generation DM(TM) company, announced today that its treatments are just what the doctor ordered for National Women's Heart Health Day, which is being commemorated next week, February 18th.The two major causes of heart disease, in women as well as men, are diabetes and high blood pressure. Women are catching up to men in their rates of diabetes, high blood pressure, and heart disease. These rates are especially high for African American, Hispanic, and Native American pre- menopausal women, and all women after the menopause.
In all, diabetes and high blood pressure affect 80 million Americans, and over 700 million people worldwide. Women make up nearly half of patients worldwide.
Diabetes and high blood pressure kill because of the complications they cause: heart disease including heart attacks and congestive heart failure; strokes; poor circulation; and kidney disease. Heart disease and kidney disease go hand in hand. Patients with kidney disease almost always die of heart disease.
Ethnic background is a huge factor. High blood pressure strikes African- Americans about twice as often as whites. A person with high blood pressure is five times more likely to end up on kidney dialysis if they're African- American than if they're white. So an African-American woman or man has a ten- fold higher risk of going on kidney dialysis than a Caucasian. Ask any African-American: they're much more likely to have a relative on kidney dialysis than the average Caucasian.
GenoMed has published the only method to reverse kidney failure due to adult-onset diabetes or high blood pressure. But the method, which is patent- pending, must be started early, before a person has lost more than half of their kidney function.
At this early stage, patients with high blood pressure or diabetes are still being seen by their primary care doctor, not by a kidney specialist. Most patients at this early stage have not even been told that they have kidney failure. So patient and physician education is necessary.
Patients have found that joining GenoMed's COIP(R) (Clinical Outcomes Improvement Program) is cost-effective, allowing them not only to obtain a license to use GenoMed's treatment, but also to pay for the education and participation of their primary care physician.
Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, said, "Heart disease due to high blood pressure or diabetes is increasing in this country, in large part because the entire population is getting older. In 2000 there were 200,000 patients on kidney dialysis. In 2010 there will be 300,000. Two- thirds of Americans die of heart disease. The epidemic of heart and kidney disease is a public health emergency. We would like people to know that a cure exists."
biz.yahoo.com |
